Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Leonard S. Schleifer

Leonard S. Schleifer

Co-founder, Chairman, and former CEO, Regeneron Pharmaceuticals

Appears in 1 story

Notable Quotes

"We have recently been working with a drug called Dupixent that we think could really bend the arc of allergic disease and change how we treat allergies, asthma, eczema, sinusitis and other allergic diseases."

Stories

Dupixent becomes one of the most versatile drugs in pharmaceutical history

New Capabilities

Serves as executive chairman; co-architect of Regeneron's science-first model

Dupixent was approved for severe eczema in 2017 as a one-disease drug. Nine years later, it's approved for nine conditions, with the latest approval (February 24, 2026) covering allergic fungal rhinosinusitis (AFRS) — which previously had no approved treatment — and reducing the need for additional surgeries and steroid courses by 92% in trials.

Updated May 29